Hyperkalemia Market

Market Overview: 

The 7 major hyperkalemia markets reached a value of US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.47% during 2024-2034.

The hyperkalemia market has been comprehensively analyzed in IMARC's new report titled "Hyperkalemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperkalemia is a medical condition characterized by increased levels of potassium in the blood. Potassium is essential to maintain the proper functioning of neurons and muscle cells, including those in the heart. Normal potassium levels range between 3.5 and 5.0 mmol/L, with levels exceeding 5.5 mmol/L classified as hyperkalemia. The symptoms of this ailment are usually few and nonspecific. Some of the indications include fatigue, muscle weakness, pain, numbness, etc. In severe cases, individuals suffering from the disorder may also experience palpitations, diarrhea, abdominal pain, shortness of breath, and abnormal heart rhythm, resulting in cardiac arrest and death. The diagnosis of hyperkalemia typically involves a blood test that measures the level of potassium in the bloodstream. The healthcare professional may perform various laboratory tests, such as serum blood urea nitrogen and creatinine, to evaluate renal function and urinalysis to screen for kidney disease. Additionally, electrocardiography (ECG) may be carried out to detect if there is a high risk of irregular heart rhythms.

The rising cases of chronic kidney diseases that affect the kidneys' ability to remove enough potassium from the body are primarily driving the hyperkalemia market. Besides this, the increasing prevalence of several associated risk factors, such as adrenal insufficiency, transfusion of blood products, hemolysis, usage of certain medications like ACE inhibitors, etc., is also augmenting the market growth. Furthermore, the widespread adoption of loop diuretics, which work by inhibiting the reabsorption of sodium and chloride in the kidneys, thereby promoting the excretion of potassium in the urine, is creating a positive outlook for the market. Apart from this, the inflating utilization of renal replacement therapy for removing extra potassium from the bloodstream and restoring the body to its physiological levels is acting as another significant growth-inducing factor. Additionally, numerous key players are making substantial investments in R&D activities to introduce a combination of effective drugs and innovative therapeutic approaches to help reduce the risk of side effects associated with high doses of individual medications. This, in turn, is also bolstering the market growth. Moreover, the ongoing development of several novel therapies for treating the ailment, such as small-molecule inhibitors and monoclonal antibodies, which target potassium channels in the body, is expected to drive the hyperkalemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hyperkalemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hyperkalemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperkalemia market in any manner.

Key Highlights:

• Hyperkalemia is more prevalent in those with chronic kidney disease, diabetes, and heart failure.
• Hyperkalemia is often categorized as mild (>5.0–5.9 mmol/L), moderate (6.0–6.4 mmol/L) and severe (≥6.5 mmol/L)
• The prevalence of hyperkalemia in the emergency department is between 3.6% and 8.8%.
• The yearly incidence of hyperkalemia is 0.96 per 100 person-years.
• Hyperkalemia affects an estimated 3.7 million persons in the United States, and the prevalence rate has grown since 2010.

Drugs:

Lokelma (Zirconium silicate) is a potassium binder indicated to treat hyperkalemia. It is produced as an oral suspension powder that removes potassium with great selectivity. The drug is taken orally, has no odor or flavor, and remains stable at room temperature.

Veltassa is recommended for the treatment of hyperkalemia in adults and children aged 12 and above. Patiromer exchanges calcium for potassium in the gastrointestinal tract, thus improving fecal potassium excretion and reducing serum potassium in individuals with hyperkalemia.

RDX013 represents a first-in-class, small molecule, targeted therapy. It has the potential to lower levels of serum potassium to treat hyperkalemia by increasing colonic secretion and fecal excretion of potassium in patients.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hyperkalemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hyperkalemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hyperkalemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hyperkalemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hyperkalemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hyperkalemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of hyperkalemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hyperkalemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hyperkalemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with hyperkalemia across the seven major markets?
• What is the size of the hyperkalemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hyperkalemia?
• What will be the growth rate of patients across the seven major markets?
   

Hyperkalemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hyperkalemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperkalemia market?
• What are the key regulatory events related to the hyperkalemia market?
• What is the structure of clinical trial landscape by status related to the hyperkalemia market?
• What is the structure of clinical trial landscape by phase related to the hyperkalemia market?
• What is the structure of clinical trial landscape by route of administration related to the hyperkalemia market?